




Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to accelerating access to affordable and innovative medicines. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe.

For more information log on to: [www.drreddys.com](http://www.drreddys.com)

## Business highlights

### Revenue mix for FY20



## Our Presence

### Commercial presence in 42 countries



<b>A</b> ALGERIA AUSTRALIA	<b>F</b> FRANCE	<b>M</b> MALAYSIA MALDIVES MEXICO MOROCCO MYANMAR	<b>R</b> ROMANIA RUSSIA	<b>U</b> UK UKRAINE US UZBEKISTAN
<b>B</b> BANGLADESH BARBADOS BELARUS BRAZIL	<b>G</b> GERMANY GHANA GUATEMALA	<b>N</b> NEPAL NEW ZEALAND	<b>S</b> SINGAPORE SOUTH AFRICA SPAIN SRI LANKA	<b>V</b> VENEZUELA VIETNAM
<b>C</b> CANADA CHILE CHINA COLOMBIA	<b>I</b> INDIA INDONESIA ITALY	<b>P</b> PERU	<b>T</b> THAILAND TRINIDAD TURKEY	
	<b>J</b> JAMAICA			
	<b>K</b> KAZAKHSTAN			

## Our core businesses

### Pharmaceutical services & active ingredients



Partner of choice

- Global leader in integrated development, manufacturing and supply of APIs.
- Contract research, development and manufacturing services.

### Global Generics



Access to affordable medicines

- Finished dosage businesses in distribution-driven unbranded as well as detailing-driven branded markets.
- North America, Europe, India, China, Russia & CIS countries are key markets in this segment.

### Proprietary Products



Fulfilling unmet medical needs

- Developing differentiated formulations that present significantly enhanced benefits in terms of efficacy, ease of use, and the resolution of unmet patient needs.

## Our History

**1984**

The birth of a dream



**1991**

From molecules to affordable medicines



**1995**

Expanding to reach patients in other countries



**2007**

Accelerating access to expensive therapies



**2010**

From medicines to health



**2015**

Re-dedicating ourselves to patient-centricity



## People

**23,000+**

Associates world wide

**45+**

Nationalities

## Infrastructure

**9**

API  
Manufacturing  
facilities

**13**

Formulations  
Manufacturing  
facilities

**9**

R&D  
facilities

**1**

Biologics  
Development  
Center

## Corporate Citizenship



“If you point to one single factor that made us what we are today, it is serving the poorest of the poor in this country. It has actually made us prosperous. Of course we didn't stop there. And we continue to bring affordable medicines to people.”

- Dr. K Anji Reddy

- + **School Improvement Program (SIP):** SIP aims at ensuring continuous quality education to students from less privileged backgrounds. Through this program, Dr. Reddy's has played an important role in shaping the lives of over 100,000 students from 229 Government schools in Andhra Pradesh and Telangana.
- + **Livelihood and Skilling:** Dr. Reddy's GROW is a skilling initiative that helps unemployed youth from marginalized sections and people with disabilities. The program has impacted over 300,000 youth through placement and training. Also, over 16,000 farmers have been benefited through MITRA, a livelihood program that aims at empowering and educating farmers.
- + **Community Health Intervention Program (CHIP):** CHIP aims at improving access to primary healthcare for people in rural communities, with a special focus on reducing the mortality rate of infants and children. The program has impacted a population of over 200,000 in 155 villages in India.
- + Support to non-profit organizations such as **CSIM, NICE** and **Naandi** Foundation.

## Recognitions

- + Winner of **Golden Peacock International Award for Sustainability** for the year 2019.
- + **Global Generics & Biosimilars Award 2019:** API supplier of the Year at the 6th Annual Global Generics & Biosimilars Awards.
- + Dr. Reddy's inclusion in the 2019 **Bloomberg Gender-Equality Index**.
- + Dr. Reddy's ranked among the **top 10 in the Forbes China 2018** list of leading Indian Companies in China.
- + **India Pharma Corporate Social Responsibility (CSR)** programme of the year Award 2018 by Department of Pharmaceuticals, Government of India.
- + **Global Generics & Biosimilar Award 2018** for CSR initiative of the year.
- + **'Best Places to Work'** in 2017 in New Jersey by NJBIZ.
- + **India's Best Companies to Work For** in the Biotechnology and Pharmaceuticals sector by Great Place To Work® Institute.
- + **India's Best Managed Boards** by Mint and Aon Hewitt and by Economic Times and Hays in their respective studies.